World of DTC Marketing

JUNE 22, 2022

PBMs, insurers, pharma companies, and hospitals don’t want to give up their profits even if it’s better for the general population. The company has hired former senior health regulators to help it navigate America’s healthcare bureaucracy. . Then there is the cost of generic drugs.

Pharmacy 227

Pharmacy Generic Drugs Life Science Branding 227

XTalks

FEBRUARY 15, 2024

US Senator Bernie Sanders, who chairs the Health, Education, Labor, and Pensions (HELP) Committee, managed to bring CEOs of major American pharma companies to a committee hearing to discuss exorbitant US drug pricing. Scapegoating PBMs has been an industry default in trying to explain exorbitant US drug prices.

Drugs 52

Drugs Pharma Companies Pharmacy Regulation 52

pharmaphorum

JUNE 20, 2022

Paul Verdin, VP of consulting and analytics, and Andreas Hadjivasiliou, managing analyst at Evaluate, tell us about the company’s Orphan Drug Report 2022, which highlights activities within the orphan drug market and forecasts what the future of the industry holds based on data.

Drugs 52

Drugs Marketing Life Science Regulation 52

XTalks

MARCH 22, 2023

In October 2022, Xtalks celebrated two decades of bringing diverse stakeholders in the life science industry together through first holding physical events, then soon after, hosting exclusively online events. In that time, we’ve gone from running 25 webinars each year to over 400, working with more than 800 expert speakers each year.

Life Science 97

Life Science Drugs FDA Approval Vaccination 97

pharmaphorum

JANUARY 10, 2023

Data is transforming life sciences, but many organisations are not using its full potential. Life sciences and the pharmaceutical industry are awash with data. The combination of health and data, he passionately believes, will transform life sciences. And he has a unique view of how data and health combine.

Marketing 98

Marketing Life Science Sales Branding 98

pharmaphorum

NOVEMBER 30, 2022

Veeva Systems invited pharmaphorum to attend its industry summit in Madrid this week, a huge event that gathered together over 1,000 individuals from life sciences and pharma. The question is, how can the journey there be accelerated, when on the horizon awaits a life sciences future very much immersed in speciality medicine?

Life Science 98

Life Science Pharma Companies Sales Marketing 98

pharmaphorum

JULY 8, 2022

The COVID-19 pandemic has catalysed significant changes in the way pharma develops drugs, particularly in the clinical trial space. We have also seen the regulators actively support the use of these hybrid decentralised research approaches. Each device type has an important role to play in hybrid and DCT trials.

Clinical Trials 100

Clinical Trials Clinical Trials Trials Regulation 100

pharmaphorum

AUGUST 31, 2021

However, like many other emerging healthcare technologies, they have been slow to gain traction and there is still confusion and scepticism around ECAs, stemming from a lack of precedence, step-by-step guidance and data to quantify their impact on drug development costs and clinical outcomes.

Clinical Trials 89

Clinical Trials Clinical Trials Life Science Trials 89

XTalks

MARCH 28, 2024

Italy-based drugmaker Italfarmaco has won US Food and Drug Administration (FDA) approval for its oral medication Duvyzat (givinostat) for the treatment of Duchenne muscular dystrophy (DMD) in patients six years of age and older. The drug generated domestic sales of $200.4 million last year, of which $131.3

FDA Approval 105

FDA Approval Genetics Gene Therapy Gene 105

pharmaphorum

DECEMBER 9, 2022

The new graduates – selected out of 75 applicants in a hotly contested application process – are working on a diverse array of digital health platforms including remote patient monitoring techniques, biomarkers, drug discovery and analytics tools, data annotation platforms, therapeutic-area data models, and novel RWE datasets.

Life Science 52

Life Science DNA Genome Genomics 52

XTalks

NOVEMBER 9, 2023

Abbott’s molecular human papillomavirus (HPV) screening solution has received approval from the US Food and Drug Administration (FDA) for detecting high-risk HPV infections and as a primary cervical cancer screening tool. The HPV test is an addition to Abbott’s Alinity m diagnostic assay family.

FDA Approval 64

FDA Approval HR Genotype Life Science 64

XTalks

JANUARY 11, 2021

Companies outsource to gain access to specialized expertise and technology, scale pharmacovigilance (PV) activities, and reduce costs. However, the efficiency and effectiveness of externalized safety activities are below expectations for many biotech and pharma companies.

Pharma Companies 90

Pharma Companies Compliance Clinical Outsourcing Regulation 90

pharmaphorum

APRIL 7, 2021

Genmab’s success has been founded on Darzalex (daratumumab), the blockbuster multiple myeloma drug that it developed in partnership with Johnson & Johnson’s Janssen unit. With other drugs in the pipeline too, van de Winkel said the company aims to continue to break new ground with next-generation antibody-based therapies.

Antibody 92

Antibody Life Science Development Regulation 92

XTalks

MAY 31, 2024

Allecra Therapeutics, a clinical-stage biopharma company focused on combating antibiotic resistance, received approval from the US Food and Drug Administration (FDA) for Exblifep (cefepime/enmetazobactam). The FDA has set a Prescription Drug User Fee Act (PDUFA) action date of October 25, 2024. percent compared to 55.0

Bacteria 52

Bacteria FDA Approval Trials Pharma Companies 52

pharmaphorum

FEBRUARY 11, 2021

Pharma companies face many challenges when involving patients in the design of clinical trials – but doing so can have huge benefits further down the line, improving the sustainability and quality of research. He said that this can be used to shape trials to make them easier for patients, with potential benefits in terms of adherence.

Clinical Trials 101

Clinical Trials Clinical Trials Trials Clinical Research 101

XTalks

MAY 6, 2022

They discussed current challenges and solutions that life science companies and clinical development organizations have with the management of clinical data. To produce ethical results in a timely manner, life science companies should ensure that they have a robust and reliable clinical data pipeline in place.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Life Science 98

pharmaphorum

SEPTEMBER 15, 2020

Pharma’s go-to-market strategies have tended to be more traditional than those seen in non-regulated sectors, but there are some signs this is changing, with an acceleration in the pace of change forced by the COVID-19 pandemic that is allowing the industry to close its gap with faster, more nimble consumer brands. “The

Branding 130

Branding Marketing Pharma Companies Life Science 130

pharmaphorum

NOVEMBER 23, 2022

A director in life sciences consulting for EY, she works within the commercial space for such companies, as well as their clients. “My I’ve always worked as a consultant for pricing and access strategies for clients, helping them to get drugs to market and access patients. Alice Blezat spoke with pharmaphorum first.

Life Science 98

Life Science Marketing Medicine Production 98

Drug Discovery World

FEBRUARY 6, 2024

As AI-designed drugs start to enter large-scale clinical trials, DDW’s Diana Spencer investigates how new digital tools are reinventing and reshaping drug discovery for the future. Quris-AI, which combines patient-on-a-chip, AI and real-time nano-sensing technologies to predict the safety and efficacy of drug candidates.

Marketing 69

Marketing Medicine Genome Genomics 69

pharmaphorum

JUNE 10, 2022

A range of pharma leaders is critical to realising these new digital opportunities, including IT, regulatory, data, digital, and R&D heads. However, pharma’s commercial leaders are uniquely positioned to drive the strategic digital shift in patient care journeys. Then, they can scale the lessons across a broader drug portfolio.

Marketing 133

Marketing Engineer Bioinformatics Regulation 133

pharmaphorum

OCTOBER 3, 2022

Gaurav Kapoor, co-founder and executive vice president of Indegene, tells pharmaphorum how pharma can take lessons from the entertainment industry and prepare for the Metaverse to enhance content engagement. Pharma companies’ customer communication methods require reimagining as technology progresses. About the author.

Branding 116

Branding Doctors Doctor Compliance 116

pharmaphorum

MAY 27, 2022

Once stakeholders are confident that technologies are adequately validated, selection based on scientific and ethical considerations can be presented to regulators in accordance with applicable legal and regulatory frameworks. There is a huge opportunity for pharma companies to capitalise on by focusing on increased DEI in clinical trials.

Clinical Trials 80

Clinical Trials Clinical Trials Trials Packaging 80

pharmaphorum

DECEMBER 16, 2020

We’ve got so many great life science assets in the UK, but there are still some gaps – manufacturing capacity being one of them.”. “We We had companies collaborating to develop laboratories. We had companies sourcing consumables for testing machines. A collaborative future.

Vaccination 122

Vaccination Vaccine Life Science In-Vitro 122

pharmaphorum

MAY 14, 2021

Long headquartered in London, the EU drug regulator is now severed from the country both physically and systematically, with its base now in Amsterdam and the UK now assessing drugs through its own regulatory agency, MHRA.

Marketing 59

Marketing Regulation Medicine Life Science 59

XTalks

JULY 10, 2023

Xtalks spoke with Kaushik Gune, Head of Healthcare (US) at Huma, a global digital health technology company, to learn more about SaMD and what it looks like to create a regulated health app. What are some examples of software as a medical device (SaMD) and how is this software regulated? Tier one devices represent the low risk.

Life Science 52

Life Science Cardiology Regulation Pharma Companies 52

Delveinsight

SEPTEMBER 8, 2021

Especially in the field of Pharmaceutical & Life Sciences, a company’s all-around product life-cycle stages, which consist of planning, designing, constructing, product testing, and commissioning processes are provided by a Pharma Consultant. Pharma Consultant. Market Assessment & Operational Sales.

Marketing 52

Marketing Production Sales Life Science 52

XTalks

SEPTEMBER 5, 2023

The EMA and other agencies have stringent regulations and guidelines that cover the design of clinical development programs for new vaccines intended to provide pre- and post-exposure prophylaxis against infectious diseases. It is affected by factors such as complacency, convenience, confidence and cultural factors.

Vaccination 96

Vaccination Vaccine Development Clinical Trials 96

XTalks

MAY 11, 2023

That mission is really important to me because I think it’s the only way we’re going to accelerate drug development in rare disease. Now it’s regulators, payers, academics, patient communities, physicians and industry all asking, “Where have you incorporated the patient voice? Well, you also need a head of patient.

Clinical Trials 97

Clinical Trials Clinical Trials Trials Development 97

Cloudbyz

MAY 19, 2021

Introduction Cell and gene therapy is an upcoming wave of therapeutic innovation in the healthcare and life sciences industry and is being pragmatically accepted worldwide. However, the major challenge is the newness and uncharted territory of the CGT field for service companies.

Gene Therapy 52

Gene Therapy Gene Manufacturing Production 52

The Pharma Data

DECEMBER 17, 2020

Kurtz brings more than 26 years of experience in global manufacturing, engineering, supply chain, CMC development and program management for drugs and devices at various stages of development. Prior to joining Cidara, Kurtz served as head of commercial API manufacturing at Gilead Sciences. AB2 Bio – Swiss pharma company AB2 Bio Ltd.

Development 52

Development Gene Therapy Engineer Life Science 52

pharmaphorum

APRIL 19, 2021

In an interview with pharmaphorum’s news editor Richard Staines, he reflected on the last year and how it could prove to be pivotal for the country’s biotech and life sciences industry. . It is really important and we have seen a lot of pharma companies interested in the UK. Speed is everything in clinical development.

Vaccination 98

Vaccination Vaccine Life Science Antibody 98

Drug Discovery World

JANUARY 26, 2023

According to research from Deloitte 1 , the average ROI in R&D for global pharma companies fell to just 1.2% The modernisation of R&D models could be key to reducing spend on new drugs, a point that Deloitte makes about the need to transform the clinical trials process. the industry experienced in 2021.

Development 98

Development Drugs Clinical Trials Clinical Trials 98

pharmaphorum

MARCH 9, 2021

Regeneron and Eli Lilly have already got antibody therapies on the market following emergency approvals by regulators including the FDA but pharma companies are beginning to focus on the threat posed by emerging variants. ExeVir is not the first company to spin out of VIB to focus on camelid antibodies.

Antibody 98

Antibody Life Science Scientist Vaccination 98

Pharmaceutical Technology

MAY 24, 2023

Every major pharma company is now involved in CGT development which has resulted in the approval of 28 therapies by the FDA thereby making CGT no longer a niche category of therapies. CGT drugs fall into two major categories: autologous and allogeneic. CGT trials operate with much lower volumes of manufactured final product.

Clinical Trials 246

Clinical Trials Clinical Trials Gene Therapy Clinical Supply Chain 246

Drug Discovery World

JANUARY 5, 2023

Frits Stulp and Aida Demneri , partners at Deloitte (including Iperion – a Deloitte business), outline how life sciences companies can play their part in driving change. It’s this kind of expanded vision for data use the major pharma companies are working towards today. To prepare for anything less would be unwise.

Life Science 52

Life Science Production Medicine Compliance 52

XTalks

OCTOBER 1, 2020

Xtalks spoke with WeiQi Lin, MD, PhD, executive vice president, research & development, and principal scientist at DURECT Corporation — a company focused on developing drugs and drug delivery methods in therapeutic areas with significant unmet need — about her transition from academia to industry. Key Moments.

Scientist 52

Scientist In-Vitro Research Life Science 52

pharmaphorum

NOVEMBER 6, 2020

“With COVID-19, the industry has realised that they need to accelerate and expedite everything they do – from identifying new targets to executing clinical studies to getting drugs onto the market.”. This fragmented landscape creates issues for pharma. “If, To learn more about how Accenture is bringing companies together, click here.

Life Science 60

Life Science Pharma Companies Production Development 60